In a CRC-bearing mouse model, YTHDF1-deficient classical DCs presented a better therapeutic effect along with anti-PD-L1 treatment compared with that of the control mice by enhancing the ability of cross-presentation of tumor antigens of DCs and promoting the activation of T cells (154). The gene discussed is CD274; the disease is colorectal carcinoma.